Business Wire

INNIO

10.8.2021 14:10:09 CEST | Business Wire | Press release

Share
INNIO Joins United Nations Global Compact Further Underscoring Commitment to Sustainability

INNIO today announced that it has joined the United Nations Global Compact , the world’s largest corporate sustainability initiative. In joining this critical voluntary leadership platform, INNIO continues its path to build on an expanded commitment to its environmental, social and governance (ESG) program. As part of the Global Compact initiative — which is focused on the development, implementation and disclosure of responsible business practices – INNIO proudly aligns itself with thousands of other companies and non-business signatories globally committed to taking responsible business action to create a better world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005096/en/

As part of its relentless pursuit to achieve a climate-neutral, greener and more secure energy future, INNIO established its Sustainability Review Board (SRB), tasked with developing INNIO’s ESG goals and strategy for its Jenbacher and Waukesha businesses in close alignment with INNIO’s growth strategy. In an act to cement its commitment to sustainability, INNIO leadership – in conjunction with its SRB – moved swiftly to become a participant of the Global Compact. INNIO recognized the Global Initiative as being a beacon platform bringing together companies and non-business signatories everywhere to align their operations and strategies with ten principles in the areas of human rights, labor, environment and anti-corruption, and to take action in support of UN goals and issues embodied in the Sustainable Development Goals. Launched in 2000, the UN Global Compact is composed of more than 9,500 companies and 3,000 non-business signatories based in over 160 countries, and more than 70 Local Networks.

“We are delighted to have taken this step to add our voice to that of thousands of others in helping to impact positive change across the world through business,” said Carlos Lange, president and CEO of INNIO. “While our expertise lies in the domain of power generation and gas compression, we recognize that our responsibility does not end with the sustainable production and delivery of electricity and gas compression. As a responsible corporate citizen, we are ethically and morally bound to maintain a responsible role as it pertains to human rights, labor, and anti-corruption as well as the environment. As part of the Global Compact, we are now positioned with our corporate neighbors to advance broader societal goals, such as the UN Sustainable Development Goals, through collaboration and innovation. Together, we can push further and faster to effectively address the world’s most pressing challenges.”

INNIO, a global provider of energy services, equipment and digital solutions for power generation and gas compression at or near the point of use, is relentlessly dedicated to being a model corporate citizen. As part of this effort, INNIO recently took a bold step in advancing sustainability in the power industry to build the first industrial scale hydrogen-fueled power plant . In close collaboration with HanseWerk Natur, INNIO initiated field testing of a 1-megawatt (MW) pilot power plant with a Jenbacher gas engine that represents the world’s first large-scale gas engine in the 1 MW range, capable of operating with variable hydrogen-natural gas mixtures or up to 100% hydrogen. INNIO’s efforts are being recognized as evidenced with its recent accolade of receiving a Silver Medal rating from EcoVadis , placing INNIO Jenbacher in the top 17% of its peers working towards sustainability.

In its capacity as a thought leader, INNIO always seeks new energy sources and better energy solutions to support its customers and their communities, while investing in its Jenbacher and Waukesha product lines and digital solutions to support the energy transition. Its gas engines—many of which have passed stringent sustainability tests for efficiency and energy savings—offer industry-leading emission levels and reduced carbon footprints. INNIO’s gas engine fleet helps to provide a more sustainable future by developing new, innovative low-carbon technologies, such as its hydrogen-ready Jenbacher gas engine technology. Its Waukesha gas engines help customers achieve low emissions and responsibly produce natural gas now and in the future. INNIO’s digital products and solutions play an important role in reduction of emissions and remote smart management of assets for our customers.

In 2021, EcoVadis awarded INNIO Jenbacher a silver medal to honor its engagement for a climate-neutral, greener, and more secure energy future. This places INNIO Jenbacher in the top 17% of its peers working towards sustainability.

About INNIO

INNIO is a leading provider of renewable gas, natural gas, and hydrogen-based solutions and services for power generation and gas compression at or near the point of use. With our Jenbacher and Waukesha gas engines, INNIO helps to provide communities, industry and the public access to sustainable, reliable and economical power ranging from 200 kW to 10 MW. We also provide life-cycle support and digital solutions to the more than 53,000 delivered gas engines globally, through our service network in more than 100 countries. We deliver innovative technology driven by decarbonization, decentralization, and digitalization to help lead the way to a greener future. Headquartered in Jenbach, Austria, the business also has primary operations in Welland, Ontario, Canada, and Waukesha, Wisconsin, U.S. For more information, visit the company's website at www.innio.com . Follow INNIO on Twitter and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye